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A case of congenital self-healing reticulohistiocytosis in an otherwise healthy newborn boy is presented. Erythematous papules cov-
ered by scales on the groin and single nodule on the left side of the forehead, which disappeared spontaneously within four months. Clin-
ical features, histological and immunohistochemical ﬁndings are described. Up to our knowledge this is the ﬁrst case described in Saudi
Arabia.
 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Full term male newborn, a product of Normal Vaginal
Delivery, primigravida and consanguineous marriage pre-
sented with erythematous papules covered by scales on
the groin (Fig. 1) and single nodule on the left side of the
forehead (Fig. 2). Skin biopsy examination revealed large
mononuclear cells and multinucleated giant cells with
ground-glass or foamy cytoplasm present in the dermis
and epidermis (Figs. 3 and 4). Immunoperoxidase staining
was positive for CD1 and S-100. Electron microscopic
study showed Langerhans cell granules (Fig. 5). Physical
examination revealed no lymphadenopathy, no organo-
megaly, complete blood count, liver function tests, andhttp://dx.doi.org/10.1016/j.jdds.2014.03.002
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were done without any evidence of systemic involvement.
The skin lesions had disappeared spontaneously within
four months. Follow-up for the baby for six month period
revealed no evidence of any relapse. The diagnosis of con-
genital self-healing reticulohistiocytosis (Hashimoto–Pritz-
ker syndrome) was considered based upon histopathogical
ﬁndings along with clinical correlation.2. Discussion
Congenital self-healing reticulohistiocytosis (CSHLCH)
or (Hashimoto–Pritzker syndrome) represents a special
form of purely cutaneous Langerhans cell histiocytosis,
ﬁrst described in 1973. This clinical entity is usually present
at birth or appears very soon thereafter. Aﬀected infants
are otherwise healthy and skin lesions tend to involute
spontaneously within weeks to months. The diagnosis of
LCH is based on histopathology which is indistinguishable
for all forms of LCH. Characteristic histopathology and
absence of other system involvement permit diﬀerentiationSaud University.
commons.org/licenses/by-nc-nd/3.0/).
Figure 3. Low power large mononuclear cells and multinucleated giant
cells with ground-glass or foamy cytoplasm present in the dermis and
epidermis.
Figure 4. High power large mononuclear cells and multinucleated giant
cells with ground-glass or foamy cytoplasm present in the dermis and
epidermis.
Figure 5. Electron microscopic study showed Langerhans cell granules.
Figure 1. Erythematous papules covered by scales on the groin.
Figure 2. Single nodule on the left side of the forehead.
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should be made only retrospectively, after exclusion of
involvement of other organs/systems (Popadic et al.,
2012). It has been described in two forms: a solitary and
a multinodular variant. Solitary or generalized lesions
can aﬀect any part of the cutaneous surface. Lesions range
from 0.2 to 2.5 cm in diameter. Lesions may grow postna-
tally. Exceptionally large tumors up to 8 cm can occur
(Alexis et al., 1991). At presentation the lesions can be pap-
ules or nodules with or without erosion or ulceration.Individual lesions are red, brown, pink, or dusky. Lesions
greater than 1 cm characteristically ulcerate as they resolve.
Lesions are asymptomatic and spontaneously involute over
8–24 weeks, leaving atrophic scarring from the ulcerated
nodules. Internal involvement is not found (Elguezabal
et al., 2011).
Histiocytosis has been reported in Saudi Arabia, a retro-
spective analysis of 21 Saudi children with Histiocytosis-X
was reviewed and follow-up from 1 to 10 years revealed
bone involvement in 19 patients and three patients died,
three had recurrences and eight had other organ dysfunc-
tion (Al-Molhim et al., 1991). However in our case there
were no systemic involvement and the disease was conﬁned
to the skin.
According to the data collected by Belhadjali et al.,
CSHLCH may be divided into two groups, the ﬁrst group
with skin lesions appeared at birth as observed in our case,
and the second group with later onset (Belhadjali et al.,
2008). Estimated incidence of LCH is 2.24–8.9 cases/one
million/year among European children (Mu¨ller et al.,
2006; Stalemark et al., 2008). The real incidence of self
healing LCH is unknown and may be underestimated due
to the spontaneous resolution and failure of clinical recog-
nition (Kapur et al., 2007).
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unknown, but the possibility of an immunological etiology
has been suggested by the occurrence of a number of
immunological abnormalities in this disease. The fact that
the lesional cell bears the phenotype of the Langerhans cell,
which is a key cell in the immune system also suggests that
the immune system is in some way involved in its pathogen-
esis. None of the immunological abnormalities, however,
have been a consistent feature, and most authors now con-
sider them to be epiphenomena (Cunliﬀe and Simpson,
2010).
On histologic examination large mononuclear cells and
multinucleated giant cells with ground-glass or foamy cyto-
plasm are present in the dermis and epidermis. Immunop-
eroxidase staining is positive for CD1, HLA-DR, and S-
100. By electron microscopy 10%–25% of cells have Lan-
gerhans cell granules. This histology is characteristic but
cannot distinguish this entity from other forms of Langer-
hans cell histiocytosis, so a deﬁnitive diagnosis cannot be
made histologically (Gadner and Grois, 1999).
Systemic evaluation is recommended, including a physi-
cal examination, complete blood count, liver function tests,
and bone survey. Liver-spleen scan and bone marrow
biopsy should be considered to rule out systemic involve-
ment (Gadner and Grois, 1999).
The diﬀerential diagnosis includes seborrhoeic dermati-
tis, juvenile xanthogranuloma, xanthoma disseminatum,
and benign cephalic histiocytosis. In disseminated Langer-
hans cell histiocytosis there may be diagnostic problems
with familial hemophagocytic lymphohistiocytosis, sinus
histiocytosis with massive lymphadenopathy, and
viral-associated hemophagocytic syndrome. Histological
examination of tissue biopsy with speciﬁc marker studies
is usually suﬃcient to diﬀerentiate Langerhans cell histiocy-
tosis from other conditions (Odom et al., 2000).
Treatment depends on the extent and the severity of the
disease. Patients with single-system bone or skin disease
have a good prognosis and often require no or only limited
treatment. In a recent study, McLelland et al showed that
in 14 patients with single-system disease, eight required
no treatment. In single-system skin disease, topical treat-
ment with 20% nitrogen mustard is eﬀective. Psoralen
and UVA (PUVA) therapy may be useful for those patients
that do not tolerate topical nitrogen mustard or fail to
respond adequately. Recent reports have shown good
response of isolated skin disease to thalidomide
(McLelland et al., 1990; Shahidi-Dadras et al., 2011),however spontaneous resolution can occur like what hap-
pened with our case.
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